



CORRECTION

Publisher Correction: Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy

Ze-bo Hu¹, Kun-ling Ma¹, Yang Zhang¹, Gui-hua Wang¹, Liang Liu¹, Jian Lu¹, Pei-pei Chen¹, Chen-chen Lu¹ and Bi-cheng Liu¹

Acta Pharmacologica Sinica (2019) 40:989–990; <https://doi.org/10.1038/s41401-019-0226-8>

Correction to: *Acta Pharmacol Sin* <https://doi.org/10.1038/aps.2017.177>, published online 05 April 2018

The REFERENCES 1–35 are wrong because of the error in the process of typesetting.

The technical editor felt very sorry for the mistake.

The correct REFERENCES 1–35 are as follows:

References

1 Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury. *Kidney Int* 1999; 56: 1627–37.

2 Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. *Nephrol Dial Transplant* 2012; 27: 3049–56.

3 Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. *Nat Rev Nephrol* 2011; 7: 327–40.

4 Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor- α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. *Metabolism* 2003; 52: 605–8.

5 Navarro JF, Mora C, Muros M, García J. Urinary tumour necrosis factor- α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. *Nephrol Dial Transplant* 2006; 21: 3428–34.

6 Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. *Diabetes* 2009; 58: 2109–18.

7 Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. *Kidney Int* 2000; 58: 1492–9.

8 Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. *J Biol Chem* 2002; 277: 18919–27.

9 Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. *Diabetes* 2007; 56: 2485–93.

10 Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. *J Biol Chem* 2000; 275: 40663–6.

11 Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. *J Leukoc Biol* 2004; 75: 267–74.

12 Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN- γ and TNF- α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. *J Immunol* 2004; 172: 6362–72.

13 Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. *J Immunol* 2004; 172: 3678–85.

14 Gutwein P, Abdel-Bakky MS, Doberstein K, Schramme A, Beckmann J, Schaefer L, et al. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. *J Cell Mol Med* 2009; 13: 3809–25.

15 Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. *Nat Rev Nephrol* 2009; 5: 713–21.

16 Ma KL, Zhang Y, Liu J, Wu Y, Hu ZB, Ruan XZ, et al. Establishment of an inflamed animal model of diabetic nephropathy. *Int J Biol Sci* 2014; 10: 149–59.

17 Tang SC, Leung JC, Lai KN. Diabetic tubulopathy: an emerging entity. *Contrib Nephrol* 2011; 170: 124–34.

18 Sanai T, Sobka T, Johnson T, el-Essawy M, Muchaneta-Kubara EC, Ben Gharbia O, et al. Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. *Diabetologia* 2000. 43: 91–100.

19 Tang SC, Yiu WH, Lin M, Lai KN. Diabetic nephropathy and proximal tubular damage. *J Ren Nutr* 2015; 25: 230–3.

20 Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. *Expert Opin Investig Drugs* 2015; 24: 283–307.

21 Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. *Cell* 2015; 160: 745–58.

¹Institute of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
Correspondence: Kun-ling Ma (klma05@163.com)

- 22 Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. *Diabetes* 1996; 45 Suppl 3: S27–30.
- 23 Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. *Proc Natl Acad Sci USA* 1993; 90: 1814–8.
- 24 Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. *Hypertens Res* 2003; 26: 413–9.
- 25 Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. *Diabetologia* 2012; 55: 2256–66.
- 26 Chen HC, Tan MS, Guh JY, Tsai JH, Lai YL. Native and oxidized low-density lipoproteins enhance superoxide production from diabetic rat glomeruli. *Kidney Blood Press Res* 2000; 23: 133–7.
- 27 Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. *Hepatology* 2008; 48: 770–81.
- 28 Ma KL, Varghese Z, Ku Y, Powis SH, Chen Y, Moorhead JF, et al. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* 2010; 298: H1646–51.
- 29 Ma KL, Zhang Y, Liu J, Wu Y, Hu ZB, Liu L, et al. Inflammatory stress induces lipid accumulation in multi-organs of db/db mice. *Acta Biochim Biophys Sin* 2015; 47: 767–74.
- 30 Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, et al. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. *Acta Diabetol* 2015; 52: 1045–56.
- 31 Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, et al. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. *Am J Physiol Endocrinol Metab* 2015; 308: E1140–8.
- 32 Liu J, Ma KL, Zhang Y, Wu Y, Hu ZB, Lv LL, et al. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. *Int J Biochem Cell Biol* 2015; 61: 8–19.
- 33 Ma KL, Liu J, Wang CX, Ni J, Zhang Y, Wu Y, et al. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. *Cardiovasc Res* 2013; 100: 450–60.
- 34 Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* 2007; 292: H2721–8.
- 35 Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, et al. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. *Arterioscler Thromb Vasc Biol* 2006; 26: 1150–5.